Want to see SE:MAGLE full AI Analyst Report?
MAGLE Stock Chart & Stats
kr17.20
-kr1.20(-3.66%)
At close: 4:00 PM EST
kr17.20
-kr1.20(-3.66%)
Day’s Range― - ―
52-Week Rangekr0.31 - kr22.80
Previous CloseN/A
Volume1.20K
Average Volume (3M)207.95K
Market Cap
kr17.10M
Enterprise Valuekr363.38
Total Cash (Recent Filing)kr2.08M
Total Debt (Recent Filing)kr343.99M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.17%
Share Statistics
EPS (TTM)-8.23
Shares Outstanding30,263,191
10 Day Avg. Volume576,640
30 Day Avg. Volume207,951
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr285.10M
Bulls Say, Bears Say
Bulls Say
CDMO PlatformThe company’s CDMO platform serves regulated pharmaceutical and biotech customers through development, analytical, API, and finished-dose production services. This diversified technical offering can support recurring customer relationships and creates a durable base for project and manufacturing revenue.
Revenue GrowthPositive TTM revenue growth indicates that customer demand and delivered contract work are still expanding despite the company’s profitability challenges. Continued top-line growth can improve operating leverage over time if management controls costs and converts activity into stronger cash generation.
Gross MarginA gross margin of approximately 54% shows that the underlying services retain meaningful value after direct costs. Although below prior-year levels, this margin provides an economic base from which better cost discipline or improved project mix could support a recovery in operating profitability.
Bears Say
Deep LossesSevere TTM losses show that the current cost structure is overwhelming gross profit, weakening the durability of earnings even while revenue grows. Persistently negative operating performance could constrain reinvestment, reduce financial resilience, and make a return to profitability dependent on substantial execution improvements.
Cash BurnLarge negative operating and free cash flow indicate that reported business activity is not currently translating into internal cash generation. Ongoing burn may require additional funding if it persists, limiting capital-allocation flexibility and increasing the financial consequences of delays in restoring profitability.
Rising LeverageDebt now exceeds equity after a material reduction in the equity cushion, consistent with loss-driven erosion. Higher leverage reduces balance-sheet flexibility, increases the impact of continued losses, and can make it harder to fund growth or absorb operating setbacks without external financing.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was kr0.31 and its highest was kr22.80 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is kr17.10M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Nov 02, 2026 which is in 32 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on Aug 12, 2026. The company reported -kr0.821 earnings per share for the quarter.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB pays a Notavailable dividend of kr0.35 which represents an annual dividend yield of 1.17%. See more information on Magle Chemoswed Holding AB dividends here
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -kr0.821 in its last earnings report. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in SE:MAGLE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
BioInvent International AB
―
Scandinavian ChemoTech AB Class B
―
Elicera Therapeutics AB
―
Spago Nanomedical AB
―
Cantargia AB
―